Will M&A Be the Next Growth Factor as BTSG's Cash Flow and Leverage Improve?
BTSG's stronger cash flow and lower leverage could give it more flexibility to pursue acquisitions and support future growth.
Zacks Investment Research9/25/2026Positive
BTSG
BrightSpring Health Services, Inc. Common StockNASDAQHEALTHCAREHEALTH INFORMATION SERVICES
Key Statistics
Market Cap
$11.20B
P/E Ratio
50.53
EPS
$1.12
Beta
1.85
52W High
$73.75
52W Low
$27.11
50-Day MA
$62.07
200-Day MA
$51.64
Dividend Yield
—
Profit Margin
2.55%
Forward P/E
22.17
PEG Ratio
—
About BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. (BTSG) is a leading provider of home and community-based health services, focusing on diverse patient populations, including individuals with intellectual and developmental disabilities and those in need of rehabilitation support. The company prioritizes personalized, high-quality care, facilitated by a dedicated and skilled workforce that significantly improves patient outcomes and quality of life. With robust investments in innovative technologies and a strong commitment to value-based care, BrightSpring is well-positioned to capitalize on growth opportunities within the dynamic healthcare landscape, highlighting its potential for sustainable, long-term success.
Fundamentals
| Revenue (TTM) | $14.37B |
| Gross Profit (TTM) | $1.78B |
| EBITDA | $626.82M |
| Operating Margin | 3.37% |
| Return on Equity | 13.00% |
| Return on Assets | 4.88% |
| Revenue/Share (TTM) | $70.11 |
| Book Value | $9.94 |
| Price-to-Book | 5.39 |
| Price-to-Sales (TTM) | 0.78 |
| EV/Revenue | 0.896 |
| EV/EBITDA | 21.17 |
| Quarterly Earnings Growth (YoY) | 196.60% |
| Quarterly Revenue Growth (YoY) | 23.00% |
| Shares Outstanding | $197.86M |
| Float | $150.65M |
| % Insiders | 3.13% |
| % Institutions | 108.39% |
Historical Volatility
HV 10-Day
31.61%
HV 20-Day
38.80%
HV 30-Day
41.07%
HV 60-Day
58.25%
HV Rank
52.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($78.94 target)
3
Strong Buy14
BuyLatest News
Best Momentum Stocks to Buy for September 24th
RDVT, BTSG and THC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 24th, 2026.
Zacks Investment Research9/24/2026Positive
3 Momentum Anomaly Stocks to Buy as Markets Surge on AI Rally
Centene, BrightSpring and Delek combine 52-week gains with short-term pullbacks, putting them in focus as momentum plays for volatile markets.
Zacks Investment Research9/22/2026Positive
BTSG Faces $200M IRA Hit but Efficiency May Protect Profitability
BTSG faces a $200M 2026 IRA revenue headwind in Home Pharmacy, but efficiency gains and technology are helping protect profitability.
Zacks Investment Research9/17/2026Positive
BrightSpring Health Services, Inc. (BTSG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BrightSpring Health Services, Inc. (BTSG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/16/2026Neutral
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now
BTSG's specialty pharmacy, infusion and home-based care expansion support growth, while IRA and execution risks may put pressure on near-term margins.
Zacks Investment Research9/15/2026Neutral
BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell?
BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.
Zacks Investment Research9/11/2026Neutral
BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?
BrightSpring Health Services' Specialty and Infusion sales rose 30%, backed by LDD growth, new launches and expansion into rare therapies.
Zacks Investment Research9/10/2026Positive
BrightSpring Health Services: 44% Ebitda Growth Is Hard To Ignore
BrightSpring Health Services is rated buy, driven by rapid profitability growth, expanding Provider Services, and reduced financial leverage. In Q2, revenue grew 23% and adjusted EBITDA surged 44%, with management raising 2026 guidance for both revenue and EBITDA. BTSG's premium 34.38x FY1 P/E is justified by strong EBITDA growth and a forward PEG of 0.73x, with multiples declining to 22.19x by FY3.
Seeking Alpha9/10/2026Positive
Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth?
BrightSpring Health Services is gaining acute infusion share with 20%+ volume growth, targeting 12-15 new states in a $20 billion market.
Zacks Investment Research9/4/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BTSG and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026